Radiation dose tied to MACE, all-cause mortality.
ONCOLOGY
Fully funded by 
Content independently selected
-
Radiation ups cardiac risk in lung cancer -
Early NSCLC: sublobar resection inferior to lobectomy for large tumors Poorer overall and cancer-specific survival confirmed in propensity-matched analysis.
-
NSCLC: meta-analysis supports sex-dependent effect for immunotherapy Magnitude of survival benefit tends to favor men.
-
Lung cancer: sarcopenia common, predicts poorer survival in meta-analysis Prevalence was 43% in patients with NSCLC, 52% in those with SCLC.
-
NSCLC: VATS sleeve lobectomy yields easier recovery, similar efficacy Less blood loss, shorter hospital stay.
-
Checkpoint inhibitors for NSCLC: efficacy for different oncogenic alterations Checkpoint inhibitors for lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
-
NSCLC: perioperative epidural analgesia fails to improve oncologic outcomes Epidural has shown reduced recurrence and mortality in other cancer types.
-
ASCO 2019 — Trilaciclib reduces topotecan-induced myelosuppression in SCLC Phase 2 trial shows no difference in PFS.
-
ASCO 2019 — Expert Commentary: Key takeaways in lung cancer David Graham, MD, says that immunotherapy is here to stay.
-
NICE approves new treatment for metastatic NSCLC Long-term survival benefit remains uncertain, especially for patients with EGFR- or ALK‑positive NSCLC
-
ASCO 2019 — Combination checkpoint blockade effective for neoadjuvant NSCLC therapy Adding ipilimumab to nivolumab boosts major pathologic response rate.
-
ASCO 2019 — Lurbinectedin shows benefit in second-line SCLC First alternative to topotecan emerges in single-group phase 2 study.
-
ASCO 2019 — Tumor mutational burden as biomarker of ICI benefit in NSCLC Phase 3 MYSTIC data also support PD-L1 expression as a marker for OS.
-
ASCO 2019 — Frontline pembrolizumab doubles median survival in advanced lung cancer KEYNOTE 189 data show benefit across TPS scores at median 18.7-month follow-up.